Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282853 | 1.00 | L3MBTL1 (0.74) | L3MBTL1SMN1; SMN2HPGDHSD17B3HDAC1 | |
| SCHEMBL9229529 | 1.00 | L3MBTL1 (0.74) | L3MBTL1SMN1; SMN2HPGDHSD17B3HDAC1 | |
| SCHEMBL4453789 | 0.98 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2HPGDHSD17B3HDAC1 | |
| SCHEMBL6606979 | 0.93 | L3MBTL1 (0.79) | L3MBTL1SMN1; SMN2HPGDHSD17B3HDAC1 | |
| SCHEMBL9346532 | 0.90 | HSD17B3 (0.67) | L3MBTL1SMN1; SMN2HPGDHSD17B3MAPT | |
| SCHEMBL964590 | 0.89 | L3MBTL1 (0.80) | L3MBTL1HSD17B3HDAC1HDAC8MAPT | |
| SCHEMBL5434100 | 0.89 | L3MBTL1 (0.80) | L3MBTL1HSD17B3HDAC1HDAC8MAPT | |
| SCHEMBL1195162 | 0.89 | L3MBTL1 (0.80) | L3MBTL1HSD17B3HDAC1HDAC8MAPT | |
| SCHEMBL2125312 | 0.89 | L3MBTL1 (0.80) | L3MBTL1HSD17B3HDAC1HDAC8MAPT | |
| SCHEMBL967963 | 0.89 | L3MBTL1 (0.80) | L3MBTL1HSD17B3HDAC1HDAC8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022273-B1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | SAINT GOBAIN (FR) | 2018-04-11 | — | — | EP | claimed |
| EP-3022273-A1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | Saint-Gobain Glass France (FR) | 2016-05-25 | — | — | EP | claimed |
| WO-2015007218-A1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | SAINT-GOBAIN GLASS FRANCE (FR) | 2015-01-22 | — | — | WO | claimed |
| EP-3022273-B1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | SAINT GOBAIN (FR) | 2018-04-11 | — | — | EP | disclosed |
| EP-3022273-A1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | Saint-Gobain Glass France (FR) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007218-A1 | LIQUID CRYSTAL POLYMER COMPOSITION, METHOD FOR PREPARING SAME, AND LIQUID CRYSTAL ARTICLE COMPRISING SAME | SAINT-GOBAIN GLASS FRANCE (FR) | 2015-01-22 | — | — | WO | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | OXER1, ESRRA, NR5A1 | L3MBTL1 1867/4885SMN1; SMN2 3288/4885HPGD 2781/4885 |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | AK1, IRAK1, CNKSR1 | L3MBTL1 1560/4885SMN1; SMN2 4402/4885HPGD 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.